Search
Close this search box.

Insights into new Alzheimer´s treatments

This episode features an interview with Ram Mukunda and Claudia Grimaldi from IGC Pharma, a clinical-stage pharmaceutical company
alzheimer

Posted on: September 13, 2023 in Blogs | Life Science Podcast | Life Science Blogs
By: Ayesha Rashid, PhD


This episode features an interview with Ram Mukunda and Claudia Grimaldi from IGC Pharma, a clinical-stage pharmaceutical company focused on improving the health and well-being of patients affected by Alzheimer’s disease and bringing therapies for it to market.

The company is currently conducting a Phase II study with IGC-AD1, an investigational low-dose tetrahydrocannabinol-(THC) based formulation that reduces neuropsychiatric symptoms such as agitation in dementia due to Alzheimer’s. The drug is the only natural THC-based investigational drug undergoing FDA trials. Ram and Claudia spoke about the compound, including clinical data from the ongoing trials evaluating it.

Ram Mukunda is the founder and CEO of IGC Pharma. Previously, he served as Chairman and CEO of Startec Global Communications Corp., Council Member at Harvard Kennedy School of Government and Council Member at Belfer Center for Science & International Affairs. Mukunda has an undergraduate and a graduate degree in biomedical engineering from the University of Maryland.

Claudia Grimaldi is currently Vice President, Principal Finance Officer, and Chief Compliance Officer at IGC. She has been with the company for almost 12 years with increasing responsibilities including managing SEC and NYSE filings, regulatory compliance and disclosures. Grimaldi is also the Managing Director of IGC Pharma Columbia, a director of the company’s subsidiary in India and a director of the board at IGC. Ms. Grimaldi is a psychologist by training, is certified as a public director by the NACD and has an MBA from Meredith College in North Carolina.

Tune into this episode to hear from the team at IGC about the company’s commitment to discovering new treatments for Alzheimer’s to help improve the lives of patients and their caregivers.

Recent Post

Follow Us

Related Posts

Psychosis in Parkinson

Parkinson’s awareness month
____________________________
Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common

Read More »